



September 11, 2015

Dear Health Care Provider,

This letter is to inform you about a recent positive result found in the Systolic Blood Pressure Intervention Trial (SPRINT), a trial in which your patient, [INSERT NAME HERE] is a participant.

As you may recall, SPRINT was designed to test whether treating systolic blood pressure to a goal of <120 mm Hg (intensive arm) reduces the risk of a composite primary outcome of non-fatal myocardial infarction, acute coronary syndrome, heart failure, non-fatal stroke, or cardiovascular death, compared with a systolic blood pressure goal of <140 mm Hg (standard arm).

The group assigned to the intensive systolic blood pressure goal of <120 mm Hg (compared to the group assigned to the 140 mm Hg goal) showed a 30% overall reduction in the risk of the events in the composite endpoint, as well as an overall lower risk of death.

Given these significant findings, we cannot continue the blood pressure goal part of the study; however, we still will need to see SPRINT participants in our clinic to collect other important information, including cognitive function and dementia testing.

At this time, we are asking all SPRINT participants to do the following:

- Keep taking their SPRINT blood pressure medications as prescribed until they see their health care provider.
- Talk to you about the blood pressure goal that is best for them. You may want to change their blood pressure medications or leave them unchanged. It is important for you to remind your patient to tell us if you are changing antihypertensives so that we can adjust what medication we give them at their next SPRINT visit.
- Your patient or you are welcome to call the SPRINT clinic to answer any questions regarding the treatment of the patient's hypertension in SPRINT.

While we are no longer treating SPRINT participants to a goal of <120 mm Hg or <140 mm Hg, we hope to see all participants over the course of the next several months to collect cognitive function and other study data, thank them for their contributions to the study, provide them with

a supply of study medications, and transition their blood pressure care back to you if this has not already transpired.

We understand that this announcement occurs in advance of the SPRINT journal publication and thus does not provide all of the data that you would normally review for clinical judgments and therapeutic decisions. We will publish the trial results as quickly as possible.

In the meantime, please contact us to answer any questions you may have about the SPRINT trial. We will also be glad to discuss with you our experiences and recommendations concerning blood pressure management of your patient who is a SPRINT participant. We welcome your review of information on www.sprinttrial.org, including the guiding principles for intensive blood pressure management in SPRINT.

Sincerely,

The SPRINT Research Team

Participant's SPRINT Clinic Contact Information:

[Site PI Name Here]

[Site Contact Information Here]